Real-World Ritlecitinib Treatment of Severe Alopecia Areata (AA) in the US: Patient Characteristics and Physician Satisfaction
Notice bibliographique
Résumé
Ritlecitinib, a JAK3/TEC family kinase inhibitor, is indicated for severe AA in patients aged ≥12 years in the US. This study describes characteristics of ritlecitinib initiators and treatment satisfaction and success. Adults ≥18 years with severe/very severe AA at ritlecitinib initiation were selected from the Adelphi Real World AA Disease Specific Programme™. This database is a cross-sectional survey of dermatologists and their AA patients [11/2023–06/2024], capturing demographics, clinical characteristics, treatment history and satisfaction, and AA impact. Subgroup analysis was conducted on patients who initiated ritlecitinib ≤2 months of the survey to assess psychosocial burden around the time of treatment initiation. 123 adults were eligible (mean age: 37.1 years, 57% male, 79% white, and 88% commercial insurance). Mean disease duration was 2.1 years. At ritlecitinib initiation, mean scalp hair loss was 71% (n=93); 73% had worsening AA. Common treatment goals were reducing hair loss (94%), improving quality-of-life (41%), and achieving long-term control (32%) (n=123). Among those who reported reasons for selecting ritlecitinib, the most common factors were its ability to reduce scalp hair loss (38%), reasonable cost-benefit ratio (28%), good overall safety profile (25%), and that it is safe for long-term use (25%). Ritlecitinib treatment duration varied among those with known treatment duration (n=111): <3 months, 33%; 3-6 months, 36%; >6 months, 31%. Among those with treatment line data (n=102), ritlecitinib was the first AA treatment for 46% of patients. Among those treated with prior AA therapies (n=60), 18% received another JAK inhibitor before ritlecitinib. Proportions of patients with hair regrowth increased with treatment duration (<3 months, 49%; 3-6 months, 72%; >6 months, 82%). Physician satisfaction with AA control was 54%, 68%, and 85% after <3, 3-6, and >6 months of ritlecitinib. 89% of patients had improving/stable hair regrowth at the time of the survey. Physicians reported treatment success for 68% in the >6-month group (n=34), but felt it was still too early to tell for 29% of patients. Among recent ritlecitinib initiators (n=26), dermatologists reported 69% of patients learned to cope with their AA; however, 84%, 73%, and 65% still reported moderate/severe embarrassment, frustration, and anxiety due to their AA, respectively. Despite many patients coping with AA, dermatologists reported substantial emotional and daily life impacts due to AA before initiating ritlecitinib. Ritlecitinib was chosen for efficacy, safety profile, and cost-benefit ratio. Hair regrowth, physician satisfaction, and perceived treatment success increased with treatment duration. While selection bias should be considered, results indicate the importance of sustained treatment for the management of patient expectations.
Récupéré en direct depuis OpenAlex et désinversé. Les résumés ne sont pas conservés dans cette base de données : les index inversés représentent 8,6 Go des 9,3 Go de texte de la base, et le serveur dispose de 13 Go libres.
Comment cette classification a été obtenuedéplier
Prédiction distillée sur la base complète
Imitation des enseignantsNi prévalence calibrée, ni vérité terrain. Validation humaine à venir. Apprise à partir de 10 348 étiquettes directes de Codex et de 10 348 étiquettes directes de Gemma. Le mode candidate est l'union des têtes enseignantes seuillées; le consensus est leur intersection. Ces sorties portent le statut machine_predicted_unvalidated et ne sont ni des étiquettes humaines ni des étiquettes directes de modèles de pointe.
Scores Codex et Gemma par catégorie
| Catégorie | Codex | Gemma |
|---|---|---|
| Métarecherche | 0,000 | 0,000 |
| Méta-épidémiologie (sens strict) | 0,000 | 0,000 |
| Méta-épidémiologie (sens large) | 0,000 | 0,000 |
| Bibliométrie | 0,000 | 0,000 |
| Études des sciences et des technologies | 0,000 | 0,000 |
| Communication savante | 0,000 | 0,000 |
| Science ouverte | 0,000 | 0,000 |
| Intégrité de la recherche | 0,000 | 0,000 |
| Charge utile insuffisante (le modèle a refusé de juger) | 0,000 | 0,000 |
Scores machine (provisoires)
Les deux têtes enseignantes du modèle étudiant, lues sur ce travail. Un score ordonne la base pour la relecture; il n'affirme jamais une catégorie, et le statut de validation accompagne chaque rangée tel quel.
Scores de référence d'un modèle non mature (critères de maturité non atteints, 7 itérations). Un score ordonne; il n'affirme jamais une catégorie.
score_only:v0-immature-baseline · tel quel depuis la passe de notation : score_only signifie que le nombre peut ordonner les travaux, et qu'aucune étiquette de catégorie n'en découleClassification
machine, non validéePrédiction automatique; un appel candidat d’une seule tête enseignante, pas un consensus.
Le détail, modèle par modèle et score par score, se trouve en fin de page sous « Comment cette classification a été obtenue ».